Saturday, February 14, 2026 2/14/2026

Monoclonal Immunoprotectants for Select Agents Toxins (Mab-SAT)

Award Number: U01AI082276
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/23/2009
PERIOD OF PERFORMANCE END DATE: 06/30/2017

Group Awards By:

View Award Description

Monoclonal Immunoprotectants for Select Agents Toxins (Mab-SAT) - DESCRIPTION (provided by applicant): Coupling a broadly applicable antibody discovery technology with a rapid, scalable manufacturing platform, human monoclonal antibody (Mab) immunoprotectants against two Category B Select Agents, Clostridium perfringens (CP) epsilon toxin (ETX) and staphylococcal enterotoxin B (SEB) will be developed. The synergistic effect of pursuing products against both toxins on a common discovery and manufacturing platform will manifest as savings in costs and time. This project will serve as a proof-of-concept for these platforms which should be generalizable for the development of human Mab immunoprotectants against other bio-warfare agents, as well as newly emerging and re-emerging infectious diseases. In Specific Aim 1, we will evaluate a panel of human anti-ETX and anti-SEB Mabs in vitro. The best neutralizers will be evaluated in Specific Aim 2 in mouse models of ETX and SEB intoxication. The three best Mabs against each toxin will be produced in a Nicotiana benthamiana manufacturing system in Specific Aim 3, and the lead Mab for ETX and SEB will be selected based on in vivo activity, expression, and stability data. In Specific Aim 4, all IND-enabling activities will be completed with a final goal of submitting INDs for each product candidate. The long-term objective of this effort is the commercialization of anti-ETX and anti-SEB Mabs. The envisioned immunoprotectants will be injectable, for prophylaxis and/or therapy in humans. The final commercialized product will be a lyophilized formulation (to be reconstituted immediately prior to injection) to maximize stability across a wide range of environmental conditions.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2018 ( Subtotal = -$44,417 )
2018	2013	MAPP BIOPHARMACEUTICAL, INC.	6160 LUSK BLVD STE 105	SAN DIEGO	CA	92121	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	5	1/12/2018	NON-COMPETING CONTINUATION	-$44,417
														Subtotal = -$44,417

Issue Date FY: 2016 ( Subtotal = $0 )
2016	2013	MAPP BIOPHARMACEUTICAL INC	6160 LUSK BOULEVARD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	5	5/3/2016	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2015 ( Subtotal = $0 )
2015	2013	MAPP BIOPHARMACEUTICAL INC	6160 LUSK BOULEVARD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	5	7/9/2015	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2013 ( Subtotal = $3,530,196 )
2013	2013	MAPP BIOPHARMACEUTICAL INC	6160 LUSK BOULEVARD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	5	6/20/2013	NON-COMPETING CONTINUATION	$3,530,196
														Subtotal = $3,530,196

Issue Date FY: 2012 ( Subtotal = $3,111,286 )
2012	2012	MAPP BIOPHARMACEUTICAL INC	6160 LUSK BOULEVARD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	4	6/28/2012	NON-COMPETING CONTINUATION	$3,111,286
														Subtotal = $3,111,286

Issue Date FY: 2011 ( Subtotal = $1,174,260 )
2011	2011	MAPP BIOPHARMACEUTICAL INC	6160 LUSK BOULEVARD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	3	8/4/2011	NON-COMPETING CONTINUATION	$1,174,260
														Subtotal = $1,174,260

Issue Date FY: 2010 ( Subtotal = $1,151,953 )
2010	2010	MAPP BIOPHARMACEUTICAL INC	6160 LUSK BOULEVARD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	2	7/22/2010	NON-COMPETING CONTINUATION	$1,151,953
														Subtotal = $1,151,953

Issue Date FY: 2009 ( Subtotal = $991,375 )
2009	2009	MAPP BIOPHARMACEUTICAL INC	6160 LUSK BOULEVARD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Allergy and Infectious Diseases Research	001	1	9/15/2009	NEW	$0
2009	2009	MAPP BIOPHARMACEUTICAL INC	6160 LUSK BOULEVARD	SAN DIEGO	CA	92121	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	1	7/21/2009	NEW	$991,375
														Subtotal = $991,375

Grand Total All Awards = $9,914,653

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Monoclonal Immunoprotectants for Select Agents Toxins (Mab-SAT)

Award Number: U01AI082276

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/23/2009

PERIOD OF PERFORMANCE END DATE: 06/30/2017

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer